Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
VirTus Respiratory Research Advances Apollo Therapeutics’ APL-10456
VirTus Respiratory Research supports the preclinical to clinical translation of Apollo Therapeutics’ APL-10456 rhinovirus vaccine, yielding positive Phase 1 data.
Biopharma R&D Trends: The Growing Complexity of Clinical Trials
Rising drug development costs and clinical trial complexity are driven by shifts toward challenging diseases like oncology and non-essential data collection.
Updated Covid-19 Vaccines Targeting XFG Variant Approved by FDA
The FDA has approved updated Covid-19 vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech targeting the dominant XFG variant ahead of immunization season.
HER3-DXd and Olaparib Combination Improves Lung Cancer Outcomes
A preclinical study shows that pairing antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib produces strong antitumour effects in lung cancer.
Evogene Deploys AI Agents for Advanced Small-Molecule Drug Discovery
Evogene restructures to focus on AI-driven computational chemistry, utilizing its ChemPass AI engine to accelerate small-molecule discovery and development.
Roche Invests $2.3B in Hanmi’s Non-GLP-1 Obesity Drug HM17321
Roche expands its pipeline by licensing Hanmi Pharm's clinical-stage UCN2 analog, HM17321, in a $2.3 billion deal targeting muscle-preserving weight loss.
Platinum & Pemetrexed Show Efficacy in Mesothelioma Post-Immunotherapy
A retrospective study shows that second-line platinum plus pemetrexed offers an 11.5-month median overall survival in pleural mesothelioma patients.
Gossamer Bio Secures $250M Funding to Advance Seralutinib for PAH Therapy
Gossamer Bio announces a $250 million private placement to fund clinical development and FDA approval of seralutinib for pulmonary arterial hypertension.
Roche Invests $750M in Oregon Plant to Expand Obesity Drug Manufacturing
Roche and Genentech are investing $750 million to expand their Oregon facility, scaling up delivery device production for upcoming obesity medications.
Nuformix Reports Positive Preclinical Data for NXP002 in Lung Fibrosis
Nuformix announced positive preclinical results for inhaled NXP002 in fibrotic lung diseases, showing promising lung exposure and anti-fibrotic activity.
FDA Grants Fast Track to Rein Therapeutics' LTI-03 for Pulmonary Fibrosis
Rein Therapeutics' LTI-03 received FDA Fast Track Designation for treating idiopathic pulmonary fibrosis following promising Phase Ib clinical trial results.
FDA Accepts Teva's Ecopipam NDA for Pediatric Tourette Syndrome Therapy
The FDA accepted Teva Pharmaceuticals' NDA for ecopipam with Priority Review. The drug aims to treat pediatric Tourette syndrome, with a decision in 2027.
3
4
5
6
7
8
9
10
11
